These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
4. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401 [TBL] [Abstract][Full Text] [Related]
6. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]
7. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
8. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240 [TBL] [Abstract][Full Text] [Related]
9. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282 [TBL] [Abstract][Full Text] [Related]
10. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355 [TBL] [Abstract][Full Text] [Related]
11. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910 [TBL] [Abstract][Full Text] [Related]
12. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
13. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer. Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417 [TBL] [Abstract][Full Text] [Related]
14. Combined BRAF, EGFR, and MEK Inhibition in Patients with Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Barras D; Missiaglia E; Wirapati P; Sieber OM; Jorissen RN; Love C; Molloy PL; Jones IT; McLaughlin S; Gibbs P; Guinney J; Simon IM; Roth AD; Bosman FT; Tejpar S; Delorenzi M Clin Cancer Res; 2017 Jan; 23(1):104-115. PubMed ID: 27354468 [TBL] [Abstract][Full Text] [Related]